photo walkheader_zpsd5bunpmi.png

Monthly Archives: November 2013

FOLFIRINOX as Neoadjuvant Therapy for Pancreatic Cancer

The idea behind treating surgically unresectable and borderline resectable pancreatic cancer (ductal adenocarcinoma of the pancreas) with chemotherapy or chemoradiation is that some minority of cases will thereupon improve to the point of now being deemed amenable to surgery, with its typically more favorable outcome.  This is generally the point then of so-called neoadjuvant therapy. […]

Cancer Diversity: Enemy of Personalized Medicine ?

In what appears to be a season of blockbuster conceptual research results in the cancer medical literature, comes a recent study involving leukemia cells but which has implications for the entire spectrum of cutting edge cancer treatment. The general current prevailing thought on the origin of cancer is that a pattern of gene mutations or […]

Biomarker miR-10b for Pancreatic Cancer: earlier diagnosis and/or therapeutic target?

As alluded to in another recent blog entry, the study of microRNA has been a source of great interest as to the possible development of biomarkers that may screen or aid on the diagnosis of pancreatic cancer (ductal adenocarcinoma of the pancreas).  MicroRNAs (or sometimes abbreviated miR) are small (18 to 25 nucleotide) non-coding RNA […]